Polypyrimidine tract-binding proteins (PTBPs) are RNA binding proteins that regulate a number of post-transcriptional events. Human PTBP1 transits between the nucleus and cytoplasm and is thought to regulate RNA processes in both. However, information about PTBP1 mRNA isoforms and regulation of PTPB1 expression remain incomplete.
INTRODUCTION
PTBP1 was first discovered as a purified protein that bound to polypyrimidine tract regions of introns (Garcia-Blanco et al. 1989 ). Initially, PTBP1 was thought to be part of the splicing machinery, until U2AF65 was discovered as the splicing factor responsible for recognizing the polyU tracts at the 3' splice site during the assembly of the spliceosome (Gil et al. 1991 ). PTBP1 has since been shown to regulate alternative exon selection during mRNA processing by repressing exon inclusion (Xue et al. 2009 ).
Although PTBP1 acts as an alternative splicing (AS) factor in the nucleus, it also shuttles between the nucleus and cytoplasm. When PTBP1 is present in the cytoplasm, it is thought to be involved in post-transcriptional regulation, processes that require capindependent translational control, RNA localization or changes in mRNA stability (Kamath et al. 2001; Romanelli et al. 2013 ). In addition to its role in molecular processes including splicing, polyadenylation, translation initiation, and mRNA stability, PTBP1 has recently been linked to the regulation of the cell cycle (Monzón-Casanova et al. 2018) .
PTBP1 is a 57 kDa protein comprised of four RNA recognition motifs (RRMs) with a bipartite nuclear localization domain (NLD) and a nuclear export signal (NES) at the N-terminus of the protein (Li and Yen 2002; Pérez et al. 1997; Wollerton et al. 2001 ).
The expression of PTBP1 is tightly regulated through alternative splicing events (Wollerton et al. 2004) . Its 15 exons have previously been shown to be alternatively spliced into three major mRNA isoforms, termed PTBP1-1, PTBP1-2, and PTBP1-4. The first described isoform, PTBP1-1 encodes a protein of 521 amino acids containing all Arake de Tacca et al.
four RRMs. The alternatively spliced isoforms, PTBP1-2 and PTBP1-4, encode an additional 19 or 26 amino acids, respectively, between the RRM2 and RRM3 domains derived from exon 9 inclusion (Garcia-Blanco et al. 1989; Valcárcel and Gebauer 1997; Sawicka et al. 2008; Romanelli et al. 2013) . Despite being very similar, the different isoforms have distinct roles in splicing and internal ribosome entry site (IRES)-mediated initiation of translation. The absence or length of the unstructured region between RRM2 and RRM3 results in differential recognition of target RNAs. These functional differences coupled with differing PTBP1 isoform ratios in different cell lines suggests that changes in relative PTBP1 isoform expression levels may be a cellular determinant of alternative splicing events (Gueroussov et al. 2015 , Wollerton et al. 2001 . For example, in the case of tropomyosin alternative splicing, PTBP1-4 represses exon 3 inclusion more than PTBP1-1 both in vivo and in vitro, whereas PTBP1-2 harbors intermediate activity (Wollerton et al. 2001) . Additionally, differences in exon 9 skipping in PTBP1 mRNAs has been found to affect the levels of many additional alternative splicing (AS) events, likely modulating the timing of transitions in the production of neural progenitors and mature neurons so as to affect brain morphology and complexity (Gueroussov et al. 2015) .
In eukaryotic mRNAs, the 5' and 3' untranslated regions (5' and 3' UTRs) serve as major cis-regulatory control elements. RNA sequences and structures in the 5' UTR and 3' UTR can act as binding sites for translation initiation factors and other RNA binding proteins to influence the translational output of an mRNA and its lifetime in the cell. To date, how the alternatively spliced isoforms of PTBP1 are connected to different 5' UTRs and 3' UTRs in PTBP1 mRNA has not been determined. Several annotation databases, such as ENSEMBL (Ensembl Release 94) (Zerbino et al. 2018 ), FANTOM5 (Riken Center for Integrative Medical Sciences (IMS)) (Noguchi et al. 2017) and NCBI Gene (O'Leary et al. 2015) , have information on PTBP1 isoforms. However, the information on UTRs differs across these databases. In ENSEMBL, the three main isoforms have distinct 5' UTRs and a common 3' UTR. In the NCBI Gene (refseq) database, PTBP1 has common 5' and 3' UTRs. The FANTOM5 database (The FANTOM Consortium and the RIKEN PMI and CLST, 2014) only accounts for two distinct 5' UTRs for PTBP1 and a common 3' UTR. Finally, the APASdb database for polyadenylation signals (You et al. 2015) reports two major polyadenylation sites within the PTBP1 3' UTR. These libraries need to be reconciled into a comprehensive model of PTBP1 transcript isoforms allowing further biochemical analysis of the regulatory pathways that influence PTBP1 mRNA isoform production and translation.
To better understand the regulation of PTBP1 mRNA isoform levels in the cell, we mapped the major PTBP1 mRNA variants present in mammalian HEK293T cells.
We analyzed the 5' UTR elements using 5'-RACE (RLM-RACE) and long-read sequencing (Oxford nanopore). We also mapped the 3' UTRs and open reading frames.
Using Western blots and mRNA reporters, we determined how the PTBP1 mRNA isoforms are translated in different stages of the cell cycle. Previous evidence revealed that human translation initiation factor eIF3, the largest translation initiation factor, crosslinks to the 5' UTR elements of several messenger RNAs, including PTBP1. While bound to mRNAs, eIF3 acts to either activate or repress their translation (Lee et al. Arake de Tacca et al. 2015) . For this reason, we also probed eIF3 interactions with PTBP1 mRNAs to determine whether eIF3 may act as a trans-acting factor regulating PTBP1 isoform translation.
RESULTS

Endogenous levels of PTBP1
Since PTBP1 has been implicated in regulating numerous processes including the cell cycle, we analyzed the endogenous levels of PTBP1 in HEK293T cells harvested in different stages of the cell cycle ( Figure 1A) . We observed that PTBP1 isoforms vary dramatically during cell cycle progression. Cells arrested in the G2 or M phases had the highest levels of all three isoforms (PTBP1-1, PTBP1-2, PTBP-4, Figure 1B) , with the upper band, comprising PTBP1-2 and PTBP1-4 (Wollerton et al. 2001) , having a higher expression profile than PTBP1-1 regardless of cell cycle phase.
All three isoforms exist at low levels in G1, and increase slightly in S, before a larger burst in G2/M occurs. Notably, PTBP1 mRNA levels do not fluctuate as much as protein levels in the different stages of the cell cycle ( Figure 1C) . Although we did not separate the contributions of translation and protein degradation, these results indicate that posttranscriptional regulation of PTBP1 expression occurs as a function of the cell cycle.
Mapping the 5' UTR, CDS and 3' UTR sequences in PTBP1 mRNAs
To test whether PTBP1 transcript isoform sequences in the ENSEMBL database are in agreement with the transcription start sites (TSS) in FANTOM5, we employed RNA Ligase Mediated Rapid Amplification of cDNA Ends (RLM-RACE) and Nanopore sequencing of mRNAs extracted from HEK293T cells to map PTBP1 transcripts (Figure 2) . Although both TSS in the FANTOM5 database were confirmed by RLM-RACE, we could not verify the presence of the 5' UTR for ENSEMBL transcript ENST00000356948.10. Notably, our RLM-RACE data supports a different TSS for ENSEMBL transcript ENST00000349038.8, 7 nucleotides (nts) 5' of the annotated TSS, in agreement with the TSS mapped in the FANTOM5 database (Figure 2) . The longer TSS for this transcript is also in agreement with the fact that eIF3 crosslinks to nucleotides 5' of the ENSEMBL-annotated TSS (Figure 2, Figure 3 ).
PTBP1 has three major protein isoforms that only differ with respect to exon 9 inclusion. PTBP1-1 lacks exon 9 completely, PTBP1-2 includes only part of exon 9 and PTBP1-4 contains the full sequence coding for exon 9 (Figure 4A ). Although differences in exon properties have been implicated in the different biological roles of PTBP1, the connectivity between the different CDS variants and the mRNA 5' UTR and 3' UTR ends is not known. To map the 5' UTRs for each predicted CDS in the PTBP1 transcript isoforms, we used a variation of the RLM-RACE methodology (Figure 4B) .
For each PTBP1 exon 9 isoform, we observed a single species by RLM-RACE, indicating one major form of 5' UTR for each CDS variant (Figure 4A and 4C) . This was confirmed by a second reaction in which we used a common inner primer to assess the amount of different PTBP1 5' UTRs in the samples (Figure 4D) , which revealed two major 5' UTR species. After sequencing the reactions individually we were able to determine the exact sequence of each transcript up to the cap region. Isoform PTBP1-1, which lacks the exon 9 sequence, extends to the 5' end of the long 5' UTR, matching the upstream TSS mapped in FANTOM5 (Figure 2A ) and the RLM-RACE experiment described above (Figure 2C) . By contrast, isoforms PTBP1-2 and PTBP1-4 which encode the truncated or full exon 9, respectively, each have the short 5' UTR, with the downstream TSS mapped in FANTOM5 (Figure 2A and 2C, Figure 4D ).
We also determined the 3' UTR sequences of PTBP1 transcript isoforms in HEK239T cells. The APASdb database (You et al. 2015) , which contains precise maps and usage quantification of different polyadenylation sites, contains two major polyadenylation sites for PTBP1 ( Figure 4E ). We used this information to design specific primers to determine the presence of each polyA site in total RNA extracted from HEK293T cells. By using a forward primer that recognizes the splice junction specific to each transcript upstream of exon 9, we could determine the 3' UTR length of each isoform by using a reverse primer on a polyA adapter ( Figure 4B) . The resulting amplification pattern could be visualized by agarose gel (Figure 4F ) and then by sequencing. Using this amplification strategy, we observed all three PTBP1 exon 9 isoforms predicted in the ENSEMBL database to have two different lengths of 3' UTR resulting from the predicted polyA sites in the APASdb database ( Figure 4E and 4F) , and possibly a third. Taken together, the present experiments define six PTBP1 transcript isoforms in HEK293T cells (Figure 5 ).
PTBP1 5' UTR and 3' UTR contributions to translation regulation
In order to assess whether the differences in PTBP1 expression through the cell cycle are related to the 5' UTRs and 3' UTRs in PTBP1 mRNAs, we used Renilla luciferase reporter mRNAs with the different PTBP1 5' UTR and 3' UTR elements in cell based assays. Using transfections of reporter mRNAs, we first assessed the relative translation levels of each reporter with respect to the cell cycle (Figure 6, Figure 7A ).
We used 6 hour transfections, as previous results have indicated that these early time points are in the linear range for mRNA transfections (Bert 2006) . During the G2 and M phases of the cell cycle, the reporter transcript with the long PTBP1 5' UTR and short (Figure 7B and 7C) . Furthermore, translation of the reporter mRNAs in the G2 and M phases also correlate well with each other (Figure 7D) . By contrast, translation in G1 and S synchronized cells did not correlate with the unsynchronized cells but rather correlated with one another (Figure 8) . These results indicate that translation in the G2 entire cell cycle, dominate translation of the reporter mRNAs with PTBP1 5' UTR and 3' UTR elements. These results are consistent with endogenous PTBP1 levels observed by Western blotting (Figure 1) , suggesting that posttranscriptional regulation of PTBP1 levels occurs to a significant extent at the level of translation during the G2 and M phases of the cell cycle.
Implications of eIF3 binding to PTBP1 mRNA on its translation
The results above suggest that translational regulation plays an important role in controlling PTBP1 isoform expression. Given the fact that eIF3 cross-links to specific sequences in the 5' UTR of PTBP1 mRNA (Lee et al., 2015) , we next tested the importance of these eIF3-5' UTR interactions in regulating PTBP1 translation. We used luciferase reporter assays to measure differences in the translation output of mRNAs with the longer PTBP1 5' UTR, which contains two sites of eIF3 crosslinking (Figure 2) , or lacking regions known to bind eIF3 ( Figure 9A) . In untreated HEK293T cells, individually deleting eIF3 crosslinking sites had a minimal impact on translation, whereas deleting both eIF3-interacting regions increased translation of these mRNAs ( Figure 9B) . In separate experiments, eIF3 immunoprecipitated from cell lysates using an antibody against EIF3B (Lee et al., 2015) was bound to all three endogenous PTBP1 coding sequence isoforms (Figure 9C) .
To check if the 5' UTR of PTBP1 is sufficient for eIF3 binding, and whether both lengths of PTBP1 5' UTR bind similarly to eIF3 across the cell cycle, we designed mRNAs with either the long or short PTBP1 5' UTR sequences upstream of a luciferase open reading frame. We also tested a reporter with a mutated 5' UTR in which the sequences that cross-link to eIF3 were deleted (Figure 2, Figure 10A ). These mRNAs were transfected into HEK293T cells, and the cells were collected in different stages of the cell cycle ( Figure 10C) . We then immunoprecipitated eIF3 from cell lysates as above (Lee et al., 2015) , followed by RNA extraction and quantitative PCR using primers for the luciferase CDS ( Figure 10C ). Upon deletion of the eIF3 crosslinking sites, eIF3 no longer bound to the reporter mRNAs ( Figure 10D) . Notably, although the longer PTBP1 5' UTR interacts with eIF3 more efficiently than the short 5' UTR, both species of 5' UTR bind to eIF3 more efficiently during the S phase and less so during G2, and even less during G1 (Figure 10D ). In the above immunoprecipitation experiments, we used a random 3' UTR instead of the 3' UTR elements derived from PTBP1 transcript isoforms to assess the influence of the PTBP1 5' UTR. To test whether eIF3 binding might also be influenced by the PTBP1 3' UTR, we designed chimeric mRNAs with different combinations of PTBP1 5' UTR and PTBP1 3' UTR, using the same reporter system (Figure 10B) . Similarly to the 5' UTR experiment (Figure 10D) , binding of the mRNAs containing the PTBP1 3' UTR to eIF3 is more prevalent during the S phase compared to the other cell phases. Interestingly, the length of the 3' UTR interacting with eIF3 changes as cell phases progresses, with a switch happening during the mitotic phase ( Figure 10E) . Altogether, these results indicate that eIF3 binds to PTBP1 mRNAs likely by interacting with both 5' UTR and 3' UTR elements in a cell cycle dependent manner (Figure 10) .
DISCUSSION
A transcript set is the collection of mRNA isoforms that originate from a given genomic sequence. Transcripts are defined by introns, exons, UTRs and their positions.
Human transcript set information is stored in large databases and browsers such as ENSEMBL, REFSEQ and UCSC (Zhao and Zhang 2015). However, cases in which the annotations of isoforms are inconsistent across databases are not uncommon (Promponas et al. 2015; Brenner 1999; Schnoes et al. 2009) . Given the existence of overlapping, variable transcript isoforms, determining the functional impact of the transcriptome requires identification of full-length transcripts, rather than just the genomic regions that are transcribed (Pelechano et al. 2013) . While working with PTBP1 mRNAs we noticed that sequences available in the ENSEMBL and FANTOM5 databases had discrepancies with respect to the transcription start sites of the major mRNA transcripts (Figure 2) . We therefore decided to validate the major mRNA isoforms for PTBP1 as the basis for future functional analysis of post-transcriptional regulation of PTBP1 expression. We were able to confirm at least six mRNA forms ( Figure 5) . These mRNA isoforms had differences in the 5' UTR, coding sequence and 3' UTR, suggesting that PTBP1 protein isoform expression may be regulated in multiple ways. PTBP1 is a pleiotropic protein, functioning in a variety of cellular processes. It is still unclear if the multiple activities of PTBP1 share a mechanistic pathway and more importantly how PTBP1 could act in posttranscriptional regulation in a tissue-specific way that is singular to the physiology of a certain set of cells. Although PTBP1 has been extensively studied, the multiple PTBP1 transcript isoforms we have identified will now enable biochemical analysis of PTBP1 mRNA regulation and function in different stages of the cell cycle.
Identifying RNA exon-exon connectivity remains a challenge when dealing with unknown mRNA isoforms. By combining long read sequencing, RNA-seq and biochemical validation, we were able to fully characterize PTPB1 transcript isoforms.
We used nanopore long read sequencing with the goal to resolve connectivity between 5' UTR, CDS and 3' UTR elements of PTBP1 mRNAs. However, due to the inability of long-read sequencing to accurately reach the 5' end of mRNA transcripts (Workman et al. 2018) , we complemented nanopore sequencing with RNA Ligase Mediated Rapid Amplification of cDNA Ends (RLM-RACE) in order to determine the full length of PTBP1 mRNA isoforms present in HEK293T cells. This approach should be useful to identify the collection of PTBP1 variants in different cell types or culture conditions (Lundberg et al. 2010) . PTBP1 mRNA has three major isoforms in the coding sequence that differ from each other at exon 9. PTBP1-1 lacks exon 9, PTBP1-2 has a partial sequence of exon 9 and PTBP1-4 has full length exon 9. Because there are three different coding sequences (CDS) (Figure 4A) , resulting in three different proteins, and two distinct lengths of 5' UTR, we aimed at determining the exact full length sequence of each transcript. We found that PTBP1-1 bears the longer 5' UTR and PTBP1-2 and PTBP1-4 Arake de Tacca et al.
both bear the shorter 5' UTR. There is only one visible band in the agarose gel for each transcript, meaning that there is only one major form of the 5' UTR for each transcript (Figure 4C) . Consistent with the APASdb database for alternative polyadenylation sites (You et al. 2015) , we identified two alternative polyadenylation sites with significant usage, resulting in each of the three major PTBP1 transcripts having two distinct 3' UTR lengths (Figure 4E and 4F) .
The mapping of all major PTBP1 transcripts in HEK293T cells (Figure 5) generated the information necessary for the biochemical analysis of PTBP1 translational regulation. Translational control elements can be located within the 5' UTR and the 3' UTR, with overall translation being affected by characteristics such as length, start-site consensus sequences as well as the presence of secondary structure, upstream AUGs, upstream open reading frames (uORFs) and internal ribosome entry sites (IRESs), and binding sites for trans-acting factors (Wilkie et al. 2003) . UTR elements have been found to be involved in regulating cell cycle dependent translation.
For example, histone translational control in Leishmania requires both 5' and 3' UTRs to properly restrict H2A translation to the S phase (Abanades et al. 2009) . Differences in 3' UTR length due to alternative polyadenylation have also been shown to result in acceleration of the cell cycle in cancer cells (Wang et al. 2018) . We found that differences in the length of PTBP1 UTRs results in altered translational efficiency as the cell cycle progresses (Figures 6-8) , which may reflect the need to regulate PTBP1 protein isoform translation quickly depending on cellular demands (Sonenberg 1994; Pesole et al. 2001; Mayr 2017) .
We previously found that eIF3 binds to PTBP1 through its 5' UTR (Lee et al. 2015 ) (Figures 2 and 3) . Here we found both lengths of 5' UTR are able to bind to eIF3 through two different sequence regions (Figure 10) . We also found that eIF3 can bind to the PTBP1 3' UTRs ( Figure 10E) . Interestingly, the different UTR lengths have differing impacts on translation (Figures 6-8 ) and eIF3 binding (Figure 9 ) in a cell cycle dependent manner. Binding of eIF3 to PTBP1 mRNA isoforms is most abundant during the S and G2 phases, with the length of the 3' UTR seeming to influence the extent of eIF3 binding. During S phase, binding is mediated predominantly through the long 3' UTR and through the 5' UTR, which correlates with overall repression of translation (Figures 1, 6-10) . During G2, eIF3 interacts only with mRNAs bearing the long 3' UTR, which correlates with repression of translation of these transcripts (Figure 6D, 7B and 7D). Consistent with eIF3 acting as a repressor, previous observations indicate that long 3' UTRs often repress translation (Szostak and Gebauer 2013; Yamashita and Takeuchi 2017) . Future experiments will be required to establish a mechanistic basis for eIF3 repression of PTBP1 mRNA translation in the S and G2 phases of the cell cycle.
Recently, PTBP1 has been found to be important for cell cycle progression. For example, PTBP1 enables germinal center B cells to progress through the late S phase of the cell cycle rapidly (Monzon-Casanova et al., 2018) . In addition, knockout of Ptbp1 in mice results in embryonic lethality due to prolonged G2 to M progression (Shibayama et al. 2009 ). Notably, we find that PTBP1 expression is highest during the G2 and M cell cycle phases (Figure 1B) , which could be explained by the increase in the cell's demand for PTBP1 in late S phase for proper cell progression. Since the levels of PTBP1 mRNA during the different stages of the cell cycle remained relatively unchanged (Figure 1C) , post-transcriptional regulation seems to be central to PTBP1 expression. With curated information on PTBP1 mRNA isoforms present in HEK293 mammalian cells (Figure 5 ), it will now be possible to dissect the post-transcriptional regulatory mechanisms involved in cell cycle dependent expression of PTBP1 isoforms, and the downstream physiological consequences.
MATERIALS AND METHODS
Cells and transfections
Human HEK293T cells were cultured in DMEM (Invitrogen) supplemented with 10% of Fetal Bovine Serum (FBS) (Seradigm) and 1% Pen/Strep (Gibco, Cat. # 15140122). RNA transfections were performed using Mirus TransIT®-mRNA Transfection Kit (Cat. # MIR 2250), with the following modifications to the manufacturer's protocol.
Sixteen hours before transfection, HEK293T cells were seeded into opaque 96-well plates to reach ~80% confluence at the time of transfection.
For each well, 9 µL of pre-warmed OptiMEM (Invitrogen) was mixed with 250 ng of RNA, 0.27 µL of Boost reagent and 0.27 µL of TransIT mRNA reagent. Reactions were incubated for 3 minutes at room temperature, added drop-wise to the well, and luciferase activity was measured 6-8 hours (as indicated) after transfection, using.
using the Renilla Luciferase assay kit (Promega, Cat. # E2820) and a Microplate 309
Luminometer (Veritas).
For G1 transfections and luminescence readouts, cells were grown to 30% confluence and compound RO3306 (Tanenbaum et al. 2015; Vassilev et al. 2006 ) was added to a 6 µM final concentration. Cells were incubated for 18 hours. After 18 hours, cells were released and incubated for two hours with fresh media. After this time, cells were transfected with the desired mRNA. Luminescence was measured after six hours of incubation. For S transfections and readouts, cells were grown to 20% confluence in standard media and thymidine was added to a final concentration of 2 mM. Cells were incubated for 18 hours in a tissue culture incubator and after 18 hours, thymidine was removed by two washes of HBSS media (Invitrogen). Fresh media was added and cells were incubated for 9 hours. After 9 hours, thymidine was added again to a 2 mM final concentration. Cells were incubated in tissue culture incubator for 15 hours. After 15 hours, cells were washed with HBSS media (Invitrogen) and released into fresh media.
After 1 hour of incubation, cells were transfected with desired mRNA and luminescence was measured after 6 hours. For G2 transfection and luminescence readouts, cells were synchronized with the same protocol as for S phase. After release, however, they were incubated for 4 hours before transfection. After transfection, cells were incubated for three hours and RO3306 was added following the previous protocol. This guaranteed the cells would not progress into M phase before luminescence was measured. Cells were then incubated for three hours and luminescence was assessed.
For M transfection and readouts, cells were treated exactly as G2, expect RO3306 was not added, allowing them to progress into M phase after four hours. Luminescence was measured after 6 hours of incubation.
Cell cycle analysis
The cell cycle analysis was performed using propidium iodide (PI) staining to determine the percent of cells in each phase of the cell cycle. HEK293T cells were fixed in 70% ethanol at the time of harvesting and stained with PI. They were treated with ribonuclease, to ensure only DNA would be stained, and 200 µL of PI (50 µg/mL) was added. They were immediately analyzed after staining on a BD Fortessa Flow
Cytometer.
Plasmids
To generate the luciferase plasmids used on this work, sections of either the PTBP1 5' UTR (GenBank accession NM_002819) or the PTBP1 3' UTR were first amplified from human cDNA extracted from HEK293T cells. These were then placed downstream of a T7 RNA polymerase promoter using overlap extension PCR and InFusion cloning. The 5' UTRs were then inserted together with Renilla luciferase into plasmid pcDNA4 V102020 (Invitrogen). The eIF3 binding mutants and PSMB6-PTBP1 chimeras were made by insertional mutagenesis with primers annealed to the pcDNA4 plasmid digested at the desired insertion site. Primers and sequences are included in Table 1 .
Western Blot
Western Blot analysis was carried out using the following antibodies: anti-EIF3B (Bethyl A301-761A), anti-HSP90 (BD 610418) and anti-PTBP1 (MABE986, clone BB7); all antibodies were used with a 1:10000 dilution.
In vitro transcription
RNAs to be used for transfections were made by in vitro transcription with T7
RNA polymerase (NEB). For luciferase mRNAs, transcription was performed in the presence of 3'-O-Me-m 7 G (5')ppp(5')G RNA Cap Structure Analogue (NEB), using linearized plasmid as template, then polyadenylated using poly-A polymerase (Invitrogen). RNAs were purified by phenol-chloroform extraction and ethanol precipitation or using the RNA clean and concentrator kit (Zymo Research). RNA quality was verified using 2% agarose gels, to ensure mRNAs were intact before transfection.
RNA Immunoprecipitation and RT-PCR
HEK293T cells grown on 10 cm plates were lysed as needed in three volumes of NP40 lysis buffer (50 mM HEPES-KOH pH=7.5, 500 mM KCl, 2 mM EDTA, 1%
Nonidet P-40 alternative, 0.5 mM DTT). Dynabeads were prepared with rabbit IgG (Cell Signaling 2729) and rabbit anti-EIF3B antibody (Bethyl A301-761A). The lysate was split into three parts, the Dynabeads-antibody mixture was added, and the suspensions incubated for 2 h at 4 ° C. The beads were washed four times with NP40 buffer, and bound RNAs were isolated by phenol chloroform extraction and ethanol precipitation.
The resulting cDNA was reverse transcribed using random hexamers and Superscript III (Thermo Fisher scientific), and PCR was performed using DNA polymerase Q5 (NEB).
Oxford Nanopore sequencing
Nanopore sequencing was carried out using the manufacturer protocol for 1D
Strand switching cDNA by ligation (SQK-LSK108). The user defined primer used was specific for exon 11 in PTBP1 mRNA: (Lee et al., 2015) , by eIF3 subunit, indicated to the left.
Annotated ENSEMBL transcripts are shown, including the 5' UTR and the beginning of the CDS, as indicated by the last 4 digits of the ENSEMBL tag (i.e. ENST0000****). Schematic of the transfection, immunoprecipitation and quantification method used to determine luciferase reporter mRNA binding to eIF3. D. Distribution of binding to eIF3 across the cell cycle for the different PTBP1 5' UTR elements as well as the deletion mutant. E. Distribution of binding to eIF3 across the cell cycle for the the different PTBP1 3' UTR elements, as well as the long form of the PTBP1 5' UTR. 
